iSchemaView has received FDA approval for its latest product, RAPID CTA, a 3D imaging platform for computed tomography angiography (CTA).

According to the company, CTA scans visualize the patients’ cerebral arteries, generally if a patient has experienced a blood clot. But interpreting the standard output will be a time-consuming process.

 “With new FDA approval and the release of RAPID CTA, we are making good on that goal. We make sure that physicians can take advantage of RAPID’s power whether they choose plain CT, CT Angiography, CT Perfusion, or MR diffusion and perfusion. It’s all about offering them the right imaging solution choice, for the right patient at the right time.” Don Listwin, CEO of iSchemaView, said in a statement.

This new technology can give doctors a complete view of blood vessels in the brain and is able to rotate the images from different angles. The CT maps have four colored overlays so that doctors and caretakers can see which part of the brain has reduced blood vessel thickness.  It only takes a few minutes for the image to set to read. The CTA scans can also be used on a mobile app or on any web browser.

“The new automated RAPID CTA tool makes it easy for community hospitals to quickly find potential candidates for treatment and for experts at the comprehensive centers to verify that the patient is right for transfer,” Greg Albers, professor of neurology at Stanford University, director of the Stanford Stroke Center, and co-founder of iSchemaView, said in a statement. “With the addition of CTA to RAPID’s FDA indications, hospitals and clinics of all sizes and locations can now use the platform to immediately review images from wherever they are. That’s powerful.”